Author

Lauren Highfield

Mass General Brigham

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Assay:protein sequence· 1

Frequent Co-Authors

Aaron N. HataiD· 2 shared Anna E. MaciagiD· 1 shared Beow Yong YeapiD· 1 shared Bin Wang· 1 shared Cathy ZhangiD· 1 shared Charlotte I. WangiD· 1 shared Daniel AndrussieriD· 1 shared Emily Hensley· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Aaron N. HataORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRASG12C suppresses PI3Kα and leads to potent tumor inhibition

Katherine Parker, Samar Ghorbanpoor, Wafa Malik, Lauren Highfield, Jamie Wang, Emily Hensley, Grace Kelley, Sarah Clark, Michela Ranieri, Soumyadip Sahu, Cathy Zhang, Magdalena A. Ploszaj, Daniel Andrussier, Hsin‐Yi Huang, Ting Chen, , Aaron N. Hata

This study shows that a dual inhibitor of KRASG12C in both ON and OFF states more effectively suppresses tumor growth than an OFF-specific inhibitor by reducing PI3K-AKT activation.

bioRxiv · Apr 30, 2026 · PreprintCancer Biology

Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer

Takashi Sakai, Zofia Piotrowska, Charlotte I. Wang, Beow Yong Yeap, Rebecca Suk Heist, Jessica J. Lin, Lauren Highfield, Jennifer L. Petersen, Mandeep K. Banwait, Joyce H. Liang, Manisha Madhavan, Aaron N. Hata, Mari A. Mino-Kenudson, Ibiayi Dagogo‐Jack

The paper identifies MTAP loss in 18% of NSCLC specimens and shows PRMT5 inhibitors are effective in MTAP-deleted tumors, with enhanced activity when combined with TKIs.

bioRxiv · Jan 23, 2026 · PreprintCancer Biology